18:35 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) reported Phase II data from a cohort of eight evaluable newly diagnosed, biomarker-positive acute myelogenous leukemia (AML) patients showing that tamibarotene (SY-1425) plus Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG) led to...
16:22 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Syros discontinues single agent tamibarotene

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) said only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to treat relapsed or refractory acute myelogenous leukemia (AML) and...
23:07 , Dec 11, 2017 |  BC Extra  |  Clinical News

Syros falls on Phase II AML, MDS data

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) lost $3.92 (32%) to $8.45 on Monday after reporting that only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to...
08:00 , Nov 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML) b-Catenin (CTNNB1); interferon regulatory factor 8 (IRF8) In vitro and mouse studies suggest simultaneously increasing IRF8 expression and inhibiting CTNNB1 could...
07:00 , Sep 10, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis Interferon regulatory factor 8 (IRF8) Studies in mice and in cell culture suggest that increasing IRF8 expression could help treat osteoporosis. Irf8-deficient...
07:00 , Jun 18, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A); interferon regulatory factor 8 (IRF8); CD6 A genomewide association study identified three...
08:00 , Feb 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML) Interferon regulatory factor 8 (IRF8; ICSBP); macrophage inflammatory protein 3 (CCL15); macrophage inflammatory protein 5 (CCL23) Studies...